Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 26

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 26
---

There
were no derivative liabilities in the three months ended September 30, 2025. In the prior year quarter, the Company recognized a $9,885
gain from marking to market the variable conversion features embedded in its then-outstanding convertible notes.

26

Nine
months ended September 30, 2025 Compared to the Nine months ended September 30, 2024

The
period-to-period comparisons of our historical results are not necessarily indicative of the results that may be expected in the future.
The results of operations data for the nine months ended September 30, 2025 and September 30, 2024 have been derived from the condensed
consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

    For the Nine Months Ended  
    Variance 

    September 30,  2025  
    September 30,  2024  
    September 30,  2025  
    September 30,  2024 
  
    Expenses: 

    Research and development 
    $2,042,890  
    $291,655  
    $1,751,235  
     600%
  
    General and administrative 
     4,057,046  
     1,341,271  
     2,715,775  
     202%
  
    Total operating expenses 
     6,099,936  
     1,632,926  
     4,467,010  
     274%

    Loss from operations 
     (6,099,936) 
     (1,632,926) 
     (4,467,010) 
     274%

    Other Income (Expenses): 

    Interest income 
     33,627  
     138  
     33,489  
     24267%
  
    Gain (loss) on change in fair value of derivative liability 
     -  
     (53,257) 
     53,257  
     -100%
  
    Interest expense 
     (3,557) 
     (217,821) 
     214,264  
     -98%
  
    Gain on extinguishment of debt 
     -  
     951,868  
     (951,868) 
     -100%
  
    Other income